NewAmsterdam Pharma Company N.V. Warrant (NAMSW NASDAQ) stock market data APIs
$24.3791
0(0%)
as of October 28, 2025
Try our APIs with
free plan!
NewAmsterdam Pharma Company N.V. Warrant Financial Data Overview
Price chart is built with
Anychart
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Prev. Close
24.3791
Open
24.3791
High
24.3791
Low
24.3791
52 wk Range
5.45-29.55
Market Cap
0
Revenue
64 006 K
Beta
0.027
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NewAmsterdam Pharma Company N.V. Warrant data using free add-ons & libraries
Get NewAmsterdam Pharma Company N.V. Warrant Fundamental Data
NewAmsterdam Pharma Company N.V. Warrant Fundamental data includes:
- Net Revenue: 64 006 K
- EBITDA: -172 616 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get NewAmsterdam Pharma Company N.V. Warrant End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NewAmsterdam Pharma Company N.V. Warrant News
New
Examining NewAmsterdam Pharma (NasdaqGM:NAMS) Valuation After Recent Share Price Rally
NewAmsterdam Pharma (NasdaqGM:NAMS) has caught investors' attention after a recent move in its stock price. With shares up 25% over the past month and 87% over the past year, many are curious about wh...
8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Continue Reading View Comments
Why NewAmsterdam Pharma (NAMS) Is Up 7.5% After Late-Stage Obicetrapib Trial Optimism
NewAmsterdam Pharma Company N.V. recently saw a spike in trader interest following optimism around its investigational drug candidate, obicetrapib, which is undergoing three pivotal late-stage trials ...
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stag...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
